liver fibrosis – Page 2

HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies

By MedXY 08/24/2025

HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.

Clinical Updates Gastroenterology news Specialties

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

By MedXY 08/01/2025

A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.

Gastroenterology Medical News news Specialties

Sharp Rise in Advanced Alcohol-Related Liver Disease Despite Stable Drinking Rates: Changing Population Risks Highlighted by US Data

By MedXY 07/31/2025

A twofold rise in advanced liver fibrosis among US heavy drinkers over two decades is linked to increased metabolic syndrome, age, and socioeconomic risk, not higher alcohol intake.